StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.32−0.03 (-7.63%)

Close on Nov 19, 2026Market cap $1.65MP/E –Yield –

RedHill Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -$9.66M. The highest annual figure on record is -$9.38M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.66M–
FY2024Dec 31, 2024-$9.38M–
FY2023Dec 31, 2023-$35.83M–
FY2022Dec 31, 2022-$29.38M–
FY2021Dec 31, 2021-$65.16M–
FY2020Dec 31, 2020-$48.99M–
FY2019Dec 31, 2019-$40.92M–
FY2018Dec 31, 2018-$34.49M–
FY2017Dec 31, 2017-$44.92M–
FY2016Dec 31, 2016-$28.34M–
FY2015Dec 31, 2015-$17.84M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2022Jun 30, 2022-$16.74M–
Q2 FY2021Jun 30, 2021-$18.90M–
Q2 FY2020Jun 30, 2020-$15.05M–
Q2 FY2019Jun 30, 2019-$10.58M–
Q2 FY2018Jun 30, 2018-$8.40M–
Q2 FY2017Jun 30, 2017-$9.83M–

More RedHill Biopharma figures

See a number that looks wrong?